AdvisorShares Trust AdvisorShares Pure US Cannabis ETF (ARCA: MSOS)

Dernières nouvelles pour AdvisorShares Trust AdvisorShares Pure US Cannabis ETF (ARCA:MSOS)

Healthcare

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from the marijuana and hemp business in the United States and in derivatives that have economic characteristics similar to such securities. It will concentrate at least 25% of its investments in the pharmaceuticals, biotechnology and life sciences industry group within the health care sector. The fund is non-diversified.

Cresco Labs Inc Sub Vtg

Blackrock Treasury Trust

Drey Inst Pref Gov Mm-M

Blackrock Treasury Trust Instl 62

AdvisorShares Pure US Cannabis ETF

<h3>Gainers</h3>
<ul>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) stock increased by 21.0% to $3.46 during Wednesday's after-market session. The market value of their outstanding shares is at $19.3 million. </li>
<li>YSX Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YSXT#NASDAQ">YSXT</a>) shares rose 6.81% to $5.8. The company's market cap stands at $125.1 million. </li>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) stock rose 5.48% to $0.73. The market value of their outstanding shares is at $13.5 million. </li>
<li>GreenTree Hospitality Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHG#NYSE">GHG</a>) stock moved upwards by 5.17% to $2.44. The company's market cap stands at $230.4 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) stock rose 4.16% to $7.01. The company's market cap stands at $135.7 million. </li>
<li>Viomi Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIOT#NASDAQ">VIOT</a>) stock increased by 3.82% to $2.43. The market value of their outstanding shares is at $186.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>EpicQuest Education Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEIQ#NASDAQ">EEIQ</a>) shares declined by 9.8% to $0.55 during Wednesday's after-market session. The company's market cap stands at $5.5 million. </li>
<li>Masterbeef (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MB#NASDAQ">MB</a>) stock declined by 9.05% to $9.45. The market value of their outstanding shares is at $152.6 million. </li>
<li>Perfect Moment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#AMEX">PMNT</a>) stock decreased by 6.95% to $0.3. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) stock declined by 6.94% to $0.94. The company's market cap stands at $10.2 million. </li>
<li>Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) shares fell 5.45% to $4.86. The market value of their outstanding shares is at $20.3 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) shares decreased by 5.23% to $1.27. The market value of their outstanding shares is at $15.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALUR

EEIQ

FTEL

PMNT

RENT

VIOT

YSXT

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) shares moved upwards by 56.4% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $25.3 million. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) stock moved upwards by 11.03% to $7.95. The market value of their outstanding shares is at $580.9 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares increased by 10.93% to $0.34. The market value of their outstanding shares is at $7.5 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock increased by 9.35% to $5.73. The market value of their outstanding shares is at $163.3 million. </li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) stock moved upwards by 7.73% to $14.2. The company's market cap stands at $930.8 million. The company's, Q2 earnings came out today. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 6.95% to $1.23. The company's market cap stands at $2.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares fell 37.7% to $1.83 during Wednesday's after-market session. The market value of their outstanding shares is at $449.9 million. </li>
<li>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) shares fell 27.66% to $29.98. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares declined by 27.33% to $2.86. The company's market cap stands at $6.9 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock declined by 9.95% to $3.26. The market value of their outstanding shares is at $34.1 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 7.59% to $1.34. The market value of their outstanding shares is at $2.3 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares fell 6.73% to $0.55. The company's market cap stands at $90.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

BMGL

CELZ

INTS

LIMN

MREO

NRIX

PSNL

RARE

ZJYL

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Ming Shing Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSW#NASDAQ">MSW</a>) shares rose 11.6% to $5.08 during Wednesday's after-market session. The company's market cap stands at $52.1 million. </li>
<li>Hydrofarm Holdings Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYFM#NASDAQ">HYFM</a>) shares moved upwards by 6.9% to $3.89. The company's market cap stands at $16.7 million. </li>
<li>Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) shares increased by 5.75% to $0.65. The company's market cap stands at $20.1 million. </li>
<li>Energys Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) shares increased by 5.28% to $2.19. The market value of their outstanding shares is at $28.9 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares moved upwards by 5.27% to $0.05. The company's market cap stands at $1.2 million. </li>
<li>SOS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOS#NYSE">SOS</a>) stock increased by 5.14% to $9.2. The company's market cap stands at $23.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) stock declined by 7.4% to $52.99 during Wednesday's after-market session. The company's market cap stands at $10.9 billion. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares decreased by 6.82% to $0.33. The market value of their outstanding shares is at $15.7 million. </li>
<li>Smart Powerr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREG#NASDAQ">CREG</a>) shares fell 5.9% to $0.22. The market value of their outstanding shares is at $5.7 million. </li>
<li>Linkers Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKS#NASDAQ">LNKS</a>) shares fell 5.09% to $0.49. The market value of their outstanding shares is at $6.7 million. </li>
<li>ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) shares declined by 4.08% to $0.68. The company's market cap stands at $322.5 million. </li>
<li>Armlogi Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOC#NASDAQ">BTOC</a>) stock declined by 4.06% to $1.42. The company's market cap stands at $63.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTOC

CHPT

CREG

ENGS

Embraer-Empresa Brasileira De Aeronautica

HYFM

LNKS

OESX

RYDE

WLGS

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares rose 9.5% to $4.5 during Wednesday's after-market session. The market value of their outstanding shares is at $10.5 million. </li>
<li>CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) shares increased by 7.5% to $2.55. The market value of their outstanding shares is at $38.9 million. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) shares moved upwards by 7.18% to $9.99. The market value of their outstanding shares is at $117.5 million. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) shares moved upwards by 6.06% to $0.53. The market value of their outstanding shares is at $9.9 million. </li>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) stock rose 4.59% to $1.82. The market value of their outstanding shares is at $62.7 million. </li>
<li>Datavault AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>) shares increased by 4.16% to $0.72. The company's market cap stands at $47.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Methode Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) stock declined by 13.5% to $8.9 during Wednesday's after-market session. The company's market cap stands at $370.8 million. As per the news, the Q4 earnings report came out today. </li>
<li>AXT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXTI#NASDAQ">AXTI</a>) shares fell 13.39% to $2.2. The company's market cap stands at $108.0 million. </li>
<li>Alpha Modus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>) shares fell 7.15% to $1.17. The company's market cap stands at $15.3 million. </li>
<li>Duos Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) shares decreased by 5.29% to $7.53. The company's market cap stands at $90.3 million. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) shares declined by 5.05% to $0.9. The market value of their outstanding shares is at $18.0 million. </li>
<li>Lightwave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) shares declined by 4.69% to $1.22. The market value of their outstanding shares is at $155.0 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

AMOD

AXTI

CPSH

DUOT

DVLT

LWLG

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

SMSI

TZUP

XTKG

12 Information Technology Stocks Moving In Wednesday's After-Market Session

FONAR Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fonr#NASDAQ">FONR</a>) ("FONAR"), The Inventor of MR Scanning&#8482;, today announced that its board of directors (the "Board") received a preliminary, non-binding proposal letter, dated July 7, 2025 from a Proposed Acquisition Group led by Timothy Damadian and consisting of certain members of the management team and Board of Directors of FONAR Corporation and third parties, to acquire all of the outstanding capital stock of FONAR not currently owned by the Proposed Acquisition Group, at a price per share anticipated to be "at a premium of no less than 10% to the average closing market price of FONAR's common stock for the 90 trading days immediately preceding July 1, 2025". The letter states that the Proposed Acquisition Group currently beneficially owns approximately 5.01% of the outstanding FONAR Stock.
The Board has established a special committee consisting of independent and disinterested directors of the Board, who will carefully review the proposal to determine the course of action that is in the best interests of the Company and all shareholders. No action is required by FONAR shareholders at this time.

News

General

FONR

FONAR Receives Preliminary Buyout Proposal From Timothy Damadian And Management-Led Group At 10%+ Premium To Average Closing Price Of Common Stock For Last 90 Days; Special Committee Formed To Review Offer

Orchid Island Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORC#NYSE">ORC</a>) is looking for Q2 Adj EPS of $0.16 vs $0.12 analyst estimate..

Guidance

Orchid Island Cap Sees Q2 Adj EPS $0.16 vs $0.12 Est

Orchid Island Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORC#NYSE">ORC</a>) is looking for Q2 GAAP EPS of $(0.29)..

Orchid Island Cap Sees Q2 GAAP EPS $(0.29)

Vermilion Energy Inc. ("Vermilion", "We", "Our", or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/VET#TSX">VET</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VET#NYSE">VET</a>) is pleased to announce that the Toronto Stock Exchange ("TSX") has approved the notice of Vermilion's intention to commence a normal course issuer bid ("NCIB") through the facilities of the TSX, New York Stock Exchange and other alternative trading platforms in Canada and the United States.
The NCIB allows Vermilion to purchase up to 15,259,187 common shares, representing approximately 10% of its public float as at June 30, 2025, over a twelve-month period commencing on July 12, 2025. The NCIB will expire no later than July 11, 2026. The total number of common shares Vermilion is permitted to purchase on the TSX is subject to a daily purchase limit of 205,865 common shares, representing 25% of the average daily trading volume of 823,460 common shares on the TSX calculated for the six-month period ended June 30, 2025; however, Vermilion may make one block purchase per calendar week which exceeds the daily repurchase restrictions. As of the close of business on June 30, 2025, Vermilion had 154,018,623 common shares issued and outstanding and a public float of 152,591,872 common shares. Any common shares that are purchased under the NCIB will be cancelled upon their purchase by Vermilion.
In connection with the NCIB, Vermilion will enter an automatic purchase plan ("ASPP") with its designated broker to allow for purchases of its common shares during self-imposed blackout periods. Such purchases would be at the discretion of the broker based on parameters provided by the Company prior to any self-imposed blackout period or any period when it is in possession of material undisclosed information. The ASPP has been pre-cleared, as required by the TSX. Outside of these blackout periods, common shares may be purchased under the NCIB in accordance with Management's discretion.
Vermilion has a long history of returning capital to its shareholders as we have paid out over $40 per share in dividends since 2003 and have had an active NCIB since 2022. The Company anticipates returning 40% of excess free cash flow(1) to shareholders in 2025, primarily through the base dividend and share repurchases. Share repurchases continue to screen as one of the most compelling options for returning capital to shareholders as we believe our common shares are trading at a price that does not reflect the appropriate value of the company.
Under its prior NCIB, which runs from July 12, 2024, to July 11, 2025, the Company was allowed to purchase up to 15,689,839 common shares. As at June 30, 2025, Vermilion repurchased an aggregate of 5,631,463 common shares under its prior NCIB at a weighted average price of $12.96 per common share, excluding brokerage fees. The company purchased all common shares through the facilities of the TSX and alternative trading platforms in Canada and the United States.

Buybacks

TSX:VET

Vermilion Energy Launches Normal Course Issuer Bid Approved To Repurchase Up To 15,259,187 Shares, Or 10% Of Float Through July 2026

MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated MGM Resorts International and provided 12-month price targets. The average target is $43.58, accompanied by a high estimate of $57.00 and a low estimate of $34.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.67%. 
<img src="https://www.benzinga.com/files/images/story/2025/1752094871_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of MGM Resorts International's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Choi</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Robin Farley</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Lizzie Dove</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Sell</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Steven Wieczynski</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Joseph Stauff</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to MGM Resorts International. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MGM Resorts International compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of MGM Resorts International's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of MGM Resorts International's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MGM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MGM Resorts International analyst ratings.</a>
<h2>Unveiling the Story Behind MGM Resorts International</h2>
MGM Resorts is the largest resort operator on the Las Vegas Strip with 37,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Park MGM, Luxor, New York-New York, and Bellagio. The Strip contributed approximately 59% of total EBITDAR in 2024. MGM also owns US regional assets, which represented a low 20s share of 2024 EBITDAR (MGM's Macao EBITDAR was 21% of the total in 2024). MGM's US sports and i-gaming operations are currently a high-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM China casinos with a new property that opened on the Cotai Strip in early 2018. We estimate MGM will open a resort in Japan in 2030.
<h3>MGM Resorts International's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Negative Revenue Trend: Examining MGM Resorts International's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -2.43% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: MGM Resorts International's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 3.47%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.05%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): MGM Resorts International's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.35%, the company may face hurdles in achieving optimal financial performance.
Debt Management: MGM Resorts International's debt-to-equity ratio is notably higher than the industry average. With a ratio of 11.03, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For MGM Resorts International's Future

Across the recent three months, 8 analysts have shared their insights on GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for GXO Logistics, revealing an average target of $53.5, a high estimate of $67.00, and a low estimate of $35.00. This current average has increased by 7.0% from the previous average price target of $50.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1752094862_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of GXO Logistics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$59.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Brian Ossenbeck</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Christian Wetherbee</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$48.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$58.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>J. Bruce Chan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Christian Wetherbee</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to GXO Logistics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of GXO Logistics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of GXO Logistics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into GXO Logistics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GXO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GXO Logistics analyst ratings.</a>
<h2>About GXO Logistics</h2>
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
<h3>GXO Logistics: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: GXO Logistics displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 21.21%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: GXO Logistics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.22% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): GXO Logistics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.27% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): GXO Logistics's ROA excels beyond industry benchmarks, reaching -0.85%. This signifies efficient management of assets and strong financial health.
Debt Management: GXO Logistics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.85, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About GXO Logistics Stock

Throughout the last three months, 9 analysts have evaluated Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $87.67, a high estimate of $97.00, and a low estimate of $75.00. This current average has increased by 4.78% from the previous average price target of $83.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1752094854_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Nasdaq among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$89.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nasdaq. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nasdaq compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Nasdaq's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nasdaq analyst ratings.</a>
<h2>Discovering Nasdaq: A Closer Look</h2>
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as the firm seeks to become a diversified technology company.
<h3>Nasdaq: Financial Performance Dissected</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Nasdaq displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 24.85%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Nasdaq's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 18.9%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 3.47%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Nasdaq's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.29%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Nasdaq's debt-to-equity ratio is below the industry average at 0.84, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NDAQ

The Analyst Verdict: Nasdaq In The Eyes Of 9 Experts

Throughout the last three months, 8 analysts have evaluated Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $275.5, a high estimate of $290.00, and a low estimate of $250.00. Surpassing the previous average price target of $261.50, the current average has increased by 5.35%.
<img src="https://www.benzinga.com/files/images/story/2025/1752094847_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Labcorp Hldgs among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$283.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$274.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$267.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$274.00</td>
<td>$285.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Labcorp Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Labcorp Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Labcorp Hldgs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>Unveiling the Story Behind Labcorp Hldgs</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Financial Milestones: Labcorp Hldgs's Journey</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Labcorp Hldgs's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.3% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Labcorp Hldgs's net margin excels beyond industry benchmarks, reaching 6.36%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Labcorp Hldgs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.6%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Labcorp Hldgs's ROA excels beyond industry benchmarks, reaching 1.18%. This signifies efficient management of assets and strong financial health.
Debt Management: Labcorp Hldgs's debt-to-equity ratio stands notably higher than the industry average, reaching 0.78. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Laboratory Corporation Of America Holdings

Demystifying Labcorp Hldgs: Insights From 8 Analyst Reviews

Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Navient, revealing an average target of $13.25, a high estimate of $16.50, and a low estimate of $12.00. Witnessing a positive shift, the current average has risen by 6.0% from the previous average price target of $12.50.
<img src="https://www.benzinga.com/files/images/story/2025/1752094839_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Navient by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$16.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.50</td>
<td>$11.00</td>
</tr>
<tr>
<td>Moshe Orenbuch</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Sell</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>John Hecht</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Navient. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Navient compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Navient's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Navient's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NAVI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Navient analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Navient Better</h2>
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
<h3>Key Indicators: Navient's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Navient's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -45.64%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Navient's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1.28%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Navient's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.08%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.0%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Navient's debt-to-equity ratio stands notably higher than the industry average, reaching 18.25. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NAVI

Forecasting The Future: 4 Analyst Projections For Navient

In the current session, the stock is trading at $176.97, after a 1.07% increase. Over the past month, Ares Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) stock increased by 4.85%, and in the past year, by 25.42%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1752094827_0.png" alt="Past Year Chart" />

<h3>How Does Ares Management P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 32.52 in the Capital Markets industry, Ares Management Inc. has a higher P/E ratio of 102.4. Shareholders might be inclined to think that Ares Management Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1752094827_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

ARES

Price Over Earnings Overview: Ares Management

Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $152.5, a high estimate of $185.00, and a low estimate of $115.00. Marking an increase of 1.46%, the current average surpasses the previous average price target of $150.31. 
<img src="https://www.benzinga.com/files/images/story/2025/1752094825_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Neurocrine Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$174.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$154.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$115.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$152.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$158.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$168.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$138.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$138.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Neurocrine Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Neurocrine Biosciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Unveiling the Story Behind Neurocrine Biosciences</h2>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>Neurocrine Biosciences: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 11.12%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Neurocrine Biosciences's net margin is impressive, surpassing industry averages. With a net margin of 1.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE stands out, surpassing industry averages. With an impressive ROE of 0.31%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Neurocrine Biosciences's ROA excels beyond industry benchmarks, reaching 0.21%. This signifies efficient management of assets and strong financial health.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below the industry average at 0.18, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NBIX

A Glimpse Into The Expert Outlook On Neurocrine Biosciences Through 14 Analysts

SS&amp;C Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) has outperformed the market over the past 15 years by 9.69% on an annualized basis producing an average annual return of 21.98%. Currently, SS&amp;C Technologies Hldgs has a market capitalization of $20.64 billion. 
Buying $100 In SSNC: If an investor had bought $100 of SSNC stock 15 years ago, it would be worth $1,954.72 today based on a price of $83.32 for SSNC at the time of writing.
<h3>SS&amp;C Technologies Hldgs's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752094815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

SSNC

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

OpenAI is preparing to introduce a new web browser powered by artificial intelligence, aiming to directly compete with Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google Chrome, which currently dominates the <a href="https://www.benzinga.com/markets/tech/25/06/46041525/google-offers-to-boost-rivals-in-search-results-to-avoid-eu-antitrust-fine-under-digital-markets-act-report">global browser market. </a>
The Details: The browser is expected to debut in the coming weeks and is designed to transform the way people interact with the web by leveraging advanced AI capabilities, according to Reuters and people familiar with the project. 
Read Next: <a href="https://www.benzinga.com/news/politics/25/07/46308025/get-ready-for-800-hours-of-blackouts-trumps-doe-warns?utm_source=articleShare">Get Ready For 800 Hours Of Blackouts, Trump&#8217;s DOE Warns</a>
<h3 class="wp-block-heading">Key Features And Strategic Goals</h3>
<ul class="wp-block-list">
<li>AI Integration:&nbsp;The browser will incorporate AI to enhance user experience, potentially keeping some interactions within a chat-based interface similar to ChatGPT, rather than directing users to external websites.</li>
<li>Platform for AI Agents:&nbsp;The browser is intended to serve as a foundation for AI agents that can perform tasks such as booking reservations or filling out forms on behalf of users, streamlining online activities.</li>
<li>User Data Access:&nbsp;By launching its own browser, OpenAI seeks more direct access to user data—a critical factor in Google&#8217;s advertising success.</li>
</ul>
Why It Matters: OpenAI&#8217;s move into internet browsers comes as Alphabet awaits a <a href="https://www.benzinga.com/markets/equities/25/06/45742430/google-could-lose-up-to-25-in-market-value-if-judge-orders-chrome-divestiture-barclays-says">pivotal antitrust remedy</a> decision, expected in August.
Alphabet could experience a share price decline of up to 25% if a federal judge mandates the divestiture of Google's Chrome browser, according to Barclays analysts. 
The DOJ has urged U.S. District Judge Amit Mehta to require Google to sell Chrome, share search data with competitors and prohibit exclusivity deals that make Google the default search engine.
Barclays identified major AI firms such as OpenAI, Anthropic and Perplexity as potential buyers if Chrome were to be sold.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46326465/unitedhealth-slammed-with-another-lawsuit-over-119-billion-stock-plunge?utm_source=articleShare">UnitedHealth Slammed With Another Lawsuit Over $119 Billion Stock Plunge</a></li>
</ul>
Photo: Shutterstock

Large Cap

Tech

GOOG

GOOGL

OpenAI Set To Unleash AI Browser Targeting Google Chrome's Dominance

Recent Financial Results
Below is a summary of certain preliminary estimates regarding our financial results for the quarter ended June 30, 2025. This preliminary financial information is based upon our estimates and is subject to completion of our financial closing procedures. Moreover, this preliminary financial information has been prepared solely on the basis of information that is currently available to, and that is the responsibility of, management. Our independent registered public accounting firm has not audited or reviewed, and does not express an opinion with respect to, this information. This preliminary financial information is not a comprehensive statement of our financial results for the quarter ended June 30, 2025, and remains subject to, among other things, the completion of our financial closing procedures, final adjustments, completion of our internal review and review by our independent registered public accounting firm of our financial statements for the quarter ended June 30, 2025.
We expect no revenue for the quarter ended June 30, 2025 and did not have revenue for the quarter ended June 30, 2024.
We expect to record a loss from operations of approximately $1.3 million for the quarter ended June 30, 2025, compared to a net loss of approximately $2.2 million for the quarter ended June 30, 2024.
As of June 30, 2025, we had total assets of approximately $2.6 million and working capital of approximately $1.2 million, including $1.8 million of cash and cash equivalents.

NDRA

ENDRA Life Sciences Expects Q2 2025 Loss Of ~$1.3M, No Revenue, And ~$2.6M In Total Assets

Trading Halt: Halted at 4:55:00 p.m. ET - Trading Halt: Halt News Pending

<ul>
<li>July 2025&nbsp;Monthly Dividend of $0.12&nbsp;Per Share of Common Stock</li>
<li>Estimated Book Value Per Share as of&nbsp;June 30, 2025&nbsp;of $7.21</li>
<li>Estimated GAAP net loss&nbsp;of $0.29&nbsp;per share for the quarter ended&nbsp;June 30, 2025, including an estimated $0.45&nbsp;per share of net realized and unrealized&nbsp;losses&nbsp;on RMBS and derivative instruments</li>
<li>Estimated&nbsp;(4.7)%&nbsp;total return on equity for the quarter ended&nbsp;June 30, 2025</li>
<li>Estimated book value, net loss&nbsp;and total return on equity amounts are preliminary, subject to change,&nbsp;and subject to review by the Company's independent registered public accounting firm</li>
<li>RMBS Portfolio Characteristics as of&nbsp;June 30, 2025</li>
<li>Next Dividend Announcement Expected&nbsp;August 13, 2025</li>
</ul>
Vero Beach, Fla., July 09, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORC#NYSE">ORC</a>) announced today that the Board of Directors of the Company declared a monthly cash dividend for the month of July 2025. The dividend of $0.12&nbsp;per share will be paid August 28, 2025&nbsp;to holders of record of the Company's common stock on July 31, 2025, with an ex-dividend date of&nbsp;July 31, 2025. The Company plans on announcing its next common stock dividend on August 13, 2025.
The Company intends to make regular monthly cash distributions to its holders of common stock. In order to qualify as a real estate investment trust ("REIT"), the Company must distribute annually to its stockholders an amount at least equal to 90% of its REIT taxable income, determined without regard to the deduction for dividends paid and excluding any net capital gain. The Company will be subject to income tax on taxable income that is not distributed and to an excise tax to the extent that a certain percentage of its taxable income is not distributed by specified dates. The Company has not established a minimum distribution payment level and is not assured of its ability to make distributions to stockholders in the future.
As of July 9, 2025, the Company had&nbsp;126,715,437&nbsp;shares of common stock outstanding. As of&nbsp;June 30, 2025, the Company had&nbsp;126,566,926&nbsp;shares of common stock outstanding. As of March 31, 2025, the Company had&nbsp;107,786,614 shares of common stock outstanding.
Estimated&nbsp;June 30, 2025&nbsp;Book Value Per Share
The Company's estimated book value per share as of&nbsp;June 30, 2025&nbsp;was $7.21.&nbsp; The Company computes book value per share by dividing total stockholders' equity by the total number of outstanding shares of common stock. At&nbsp;June 30, 2025, the Company's preliminary estimated total stockholders' equity was approximately $912.0 million&nbsp;with&nbsp;126,566,926&nbsp;shares of common stock outstanding. These figures and the resulting estimated book value per share are preliminary, subject to change, and subject to review by the Company's independent registered public accounting firm.&nbsp;
Estimated Net Loss&nbsp;Per Share&nbsp;and Realized and Unrealized Losses on RMBS and Derivative Instruments
The Company estimates it generated a net loss&nbsp;per share of $0.29&nbsp;for the quarter ended&nbsp;June 30, 2025,&nbsp;which includes an estimated $0.45&nbsp;per share&nbsp;of net realized and unrealized&nbsp;losses on RMBS and derivative instruments.&nbsp;These amounts compare to total dividends declared during the quarter of $0.36&nbsp;per share.&nbsp;Net&nbsp;loss&nbsp;per common share calculated under generally accepted accounting principles can, and does, differ from our REIT taxable income.&nbsp; The Company views REIT taxable income as a better indication of income to be paid in the form of a dividend rather than net income. Many components of REIT taxable income can only be estimated at this time and our monthly dividends declared are based on both estimates of REIT taxable income to be earned over the course of the current quarter and calendar year and a longer-term estimate of the REIT taxable income of the Company. These figures are preliminary, subject to change, and subject to review by the Company's independent registered public accounting firm.&nbsp;
Estimated Total Return on Equity
The Company's estimated total return on equity for the quarter ended&nbsp;June 30, 2025&nbsp;was&nbsp;(4.7)%. The Company calculates total return on equity as the sum of dividends declared and paid during the quarter plus changes in book value during the quarter, divided by the Company's stockholders' equity at the beginning of the quarter.&nbsp; The total return was $(0.37)&nbsp;per share, comprised of dividends per share of $0.36&nbsp;and a decrease in book value per share of $(0.73)&nbsp;from March 31, 2025.

Comments

AdvisorShares Trust AdvisorShares Pure US Cannabis ETF

Actualités

Dernières nouvelles pour AdvisorShares Trust AdvisorShares Pure US Cannabis ETF (ARCA:MSOS)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL